Literature DB >> 9842969

Describing patients' normal tissue reactions: concerning the possibility of individualising radiotherapy dose prescriptions based on potential predictive assays of normal tissue radiosensitivity. Steering Committee of the BioMed2 European Union Concerted Action Programme on the Development of Predictive Tests of Normal Tissue Response to Radiation Therapy.

N G Burnet1, J Johansen, I Turesson, J Nyman, J H Peacock.   

Abstract

Clinical radiotherapeutic doses are limited by the tolerance of normal tissues. Patients given a standard treatment exhibit a range of normal tissue reactions, and a better understanding of this individual variation might allow for individualisation of radiotherapeutic prescriptions, with consequent improvement in the therapeutic ratio. At present, there is no simple way to describe normal tissue reactions, which hampers communication between clinic and laboratory and between groups from different centres. There is also no method for comparing the severity of reactions in different normal tissues. This arises largely because there is no definition of a "normal" reaction, an "extreme" reaction or the particular term "over-reactor" (OR). This report proposes definitions for these terms, as well as a simple terminology for describing normal tissue reactions in patients having radiotherapy. The "normal" range represents the individual variation in normal tissue reactions amongst large numbers of patients treated in the same way which is within clinically acceptable limits. The term "OR" is applied to an individual whose reaction is more severe than the normal range but also implies that this forced a major change in the radiotherapeutic prescription or that the reactions were very severe or fatal. A "severe OR" would develop serious problems with a typical radical dose, while an "extreme OR" would have such difficulties at a much lower dose. To describe the normal range, a numerical scale is suggested, from 1 to 5, resistant to sensitive. The term "highly radiosensitive" (HR) is suggested for category 5. An "informal" relative scale, as suggested here, is quick and simple. It should allow comparison between different hospitals, compensate for differences in radiotherapeutic dose and technique and allow comparison of reactions between different anatomical sites. It should be adequate for discriminating patients at the extremes of the normal range from those at the centre. It is hoped that the definitions and terminology proposed here will aid communication in the field of predictive testing of normal tissue radiosensitivity.

Entities:  

Mesh:

Year:  1998        PMID: 9842969     DOI: 10.1002/(sici)1097-0215(19981218)79:6<606::aid-ijc9>3.0.co;2-y

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  In vitro prediction of breast cancer therapy toxicity.

Authors:  Michael J McKay; Jezzie Maneerat; Timothy M McKay; Jeremy N McKay; Reza Masoud-Rahbari
Journal:  Ann Transl Med       Date:  2017-03

2.  Incorporating single-nucleotide polymorphisms into the Lyman model to improve prediction of radiation pneumonitis.

Authors:  Susan L Tucker; Minghuan Li; Ting Xu; Daniel Gomez; Xianglin Yuan; Jinming Yu; Zhensheng Liu; Ming Yin; Xiaoxiang Guan; Li-E Wang; Qingyi Wei; Radhe Mohan; Yevgeniy Vinogradskiy; Mary Martel; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-27       Impact factor: 7.038

Review 3.  Defining molecular and cellular responses after low and high linear energy transfer radiations to develop biomarkers of carcinogenic risk or therapeutic outcome.

Authors:  Michael Story; Liang-hao Ding; William A Brock; K Kian Ang; Ghazi Alsbeih; John Minna; Seongmi Park; Amit Das
Journal:  Health Phys       Date:  2012-11       Impact factor: 1.316

4.  A novel high-throughput irradiator for in vitro radiation sensitivity bioassays.

Authors:  Tyler L Fowler; Regina K Fulkerson; John A Micka; Randall J Kimple; Bryan P Bednarz
Journal:  Phys Med Biol       Date:  2014-02-28       Impact factor: 3.609

Review 5.  Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?

Authors:  Carsten Herskind; Christopher J Talbot; Sarah L Kerns; Marlon R Veldwijk; Barry S Rosenstein; Catharine M L West
Journal:  Cancer Lett       Date:  2016-03-02       Impact factor: 8.679

6.  Enhanced intrinsic radiosensitivity after treatment with stereotactic radiosurgery for an acoustic neuroma.

Authors:  Gerard Adams; Olga A Martin; Daniel E Roos; Pavel N Lobachevsky; Andrew E Potter; Andrew C Zacest; Eva Bezak; William M Bonner; Roger F Martin; Trevor Leong
Journal:  Radiother Oncol       Date:  2012-05-03       Impact factor: 6.280

Review 7.  Late Sequelae of Radiotherapy—The Effect of Technical and Conceptual Innovations in Radiation Oncology.

Authors:  Ulrike Hoeller; Kerstin Borgmann; Michael Oertel; Uwe Haverkamp; Volker Budach; Hans Theodor Eich
Journal:  Dtsch Arztebl Int       Date:  2021-03-26       Impact factor: 5.594

8.  Prolonged expression of the γ-H2AX DNA repair biomarker correlates with excess acute and chronic toxicity from radiotherapy treatment.

Authors:  Emma C Bourton; Piers N Plowman; Daniel Smith; Colin F Arlett; Christopher N Parris
Journal:  Int J Cancer       Date:  2011-04-13       Impact factor: 7.396

9.  Combined low initial DNA damage and high radiation-induced apoptosis confers clinical resistance to long-term toxicity in breast cancer patients treated with high-dose radiotherapy.

Authors:  Luis Alberto Henríquez-Hernández; Ruth Carmona-Vigo; Beatriz Pinar; Elisa Bordón; Marta Lloret; María Isabel Núñez; Carlos Rodríguez-Gallego; Pedro C Lara
Journal:  Radiat Oncol       Date:  2011-06-06       Impact factor: 3.481

Review 10.  Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype.

Authors:  Gillian C Barnett; Catherine M L West; Alison M Dunning; Rebecca M Elliott; Charlotte E Coles; Paul D P Pharoah; Neil G Burnet
Journal:  Nat Rev Cancer       Date:  2009-01-16       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.